Narcotic antagonists – Naloxone hydrochloride MCQs With Answer
This concise, Student-friendly post explains naloxone hydrochloride — a key narcotic antagonist used in emergency pharmacology. B.Pharm students will learn about naloxone’s mechanism as a competitive opioid receptor antagonist, clinical uses in opioid overdose and respiratory depression, pharmacokinetics (onset, duration, bioavailability), routes and formulations (IV, IM, intranasal), dosing principles, adverse effects including precipitated withdrawal, and differences from long‑acting antagonists like naltrexone. These focused keywords — naloxone hydrochloride, narcotic antagonist, opioid antagonism, overdose reversal, pharmacology, B.Pharm MCQs — will help reinforce core concepts and exam readiness. Now let’s test your knowledge with 50 MCQs on this topic.
Q1. Which opioid receptor does naloxone have the highest antagonistic affinity for?
- Delta (δ) receptor
- Kappa (κ) receptor
- Mu (μ) receptor
- ORL-1 (nociceptin) receptor
Correct Answer: Mu (μ) receptor
Q2. What is the primary clinical indication for naloxone hydrochloride?
- Chronic pain management
- Opioid overdose with respiratory depression
- Treatment of anxiety disorders
- Reduction of fever in infections
Correct Answer: Opioid overdose with respiratory depression
Q3. Naloxone reverses opioid effects by which mechanism?
- Noncompetitive allosteric inhibition of opioid receptors
- Agonist activity at mu receptors
- Competitive antagonism at opioid receptors
- Inhibition of opioid metabolism
Correct Answer: Competitive antagonism at opioid receptors
Q4. Why is orally administered naloxone generally ineffective for reversing systemic opioid effects?
- Poor receptor affinity
- Extensive first-pass hepatic metabolism
- Inability to cross the blood-brain barrier under any condition
- Inactivation by gastric acid only
Correct Answer: Extensive first-pass hepatic metabolism
Q5. Which route of administration provides the fastest clinical onset of naloxone?
- Oral
- Intramuscular
- Intravenous
- Intranasal
Correct Answer: Intravenous
Q6. A commonly recommended initial IV dose range for naloxone in adults is:
- 0.001–0.01 mg
- 0.1–0.2 mg
- 0.4–2 mg
- 10–20 mg
Correct Answer: 0.4–2 mg
Q7. Which naloxone formulation is designed for easy public use and rapid intranasal delivery?
- Oral tablet
- Naloxone transdermal patch
- 4 mg intranasal spray (e.g., Narcan)
- Extended-release injection
Correct Answer: 4 mg intranasal spray (e.g., Narcan)
Q8. The duration of naloxone’s antagonistic action compared to many opioids is generally:
- Longer than most opioids, preventing re-narcotization
- Shorter than many opioids, risking re-narcotization
- Indefinite once administered
- Exactly identical for all opioids
Correct Answer: Shorter than many opioids, risking re-narcotization
Q9. Which adverse effect is commonly triggered by naloxone in opioid-dependent patients?
- Severe hypotension without other symptoms
- Precipitated acute withdrawal (agitation, vomiting)
- Chronic constipation
- Increased sedation lasting 48 hours
Correct Answer: Precipitated acute withdrawal (agitation, vomiting)
Q10. For pediatric naloxone dosing in an acute emergency, the usual initial IV/IM dose is approximately:
- 0.0001 mg/kg
- 0.01 mg/kg
- 0.5 mg/kg
- 5 mg/kg
Correct Answer: 0.01 mg/kg
Q11. Which statement about naloxone’s blood-brain barrier penetration is most accurate?
- Naloxone does not cross the blood-brain barrier at therapeutic doses
- Naloxone crosses the blood-brain barrier sufficiently to reverse central opioid effects
- Naloxone accumulates exclusively in peripheral tissues
- Naloxone requires active transport into the CNS
Correct Answer: Naloxone crosses the blood-brain barrier sufficiently to reverse central opioid effects
Q12. Compared to naloxone, naltrexone is best described as:
- A short-acting antagonist used for emergency reversal
- A long-acting opioid antagonist used in maintenance therapy
- An opioid agonist with longer duration
- An antiemetic unrelated to opioids
Correct Answer: A long-acting opioid antagonist used in maintenance therapy
Q13. Which pharmacokinetic property explains the need for repeated naloxone dosing after initial reversal?
- High oral bioavailability
- Short plasma half-life relative to some opioids
- Irreversible receptor binding
- Slow renal clearance causing accumulation
Correct Answer: Short plasma half-life relative to some opioids
Q14. Naloxone is most effective in reversing which opioid effect first?
- Miosis (pupil constriction)
- Respiratory depression
- Constipation
- Analgesia lasting days
Correct Answer: Respiratory depression
Q15. Which interaction may reduce the apparent efficacy of naloxone in reversing overdose?
- Co-ingestion of benzodiazepines causing additional respiratory depression
- Presence of naloxone metabolites that enhance activity
- Presence of antibiotics in the bloodstream
- Concurrent use of antihistamines increasing naloxone potency
Correct Answer: Co-ingestion of benzodiazepines causing additional respiratory depression
Q16. In a patient on high-dose methadone, naloxone reversal may require:
- No naloxone because methadone is unaffected
- Lower doses than usual due to synergy
- Higher or repeated naloxone dosing because of methadone’s long duration
- Antibiotic coadministration to boost naloxone
Correct Answer: Higher or repeated naloxone dosing because of methadone’s long duration
Q17. Which property of naloxone makes it suitable for intranasal use in community settings?
- High oral bioavailability
- Rapid onset via mucosal absorption and ease of administration
- Requirement for dilution before use
- Need for surgical implantation
Correct Answer: Rapid onset via mucosal absorption and ease of administration
Q18. Which effect is least likely to be reversed by naloxone in mixed overdoses?
- Opioid-induced respiratory depression
- Opioid-induced miosis
- Benzodiazepine-induced hypoventilation
- Opioid analgesia
Correct Answer: Benzodiazepine-induced hypoventilation
Q19. Naloxone’s chemical form used in injections is typically:
- Naloxone base as a free base solution
- Naloxone sulfate crystalline powder
- Naloxone hydrochloride salt in aqueous solution
- Naloxone ester prodrug
Correct Answer: Naloxone hydrochloride salt in aqueous solution
Q20. Re-narcotization after naloxone administration occurs because:
- Naloxone permanently removes opioids from receptors
- Naloxone metabolism produces opioid agonists
- The opioid has a longer duration than naloxone, leading to return of effects
- Naloxone stimulates opioid release from tissues
Correct Answer: The opioid has a longer duration than naloxone, leading to return of effects
Q21. Which monitoring parameter is most critical after administering naloxone for suspected overdose?
- Blood sugar levels only
- Continuous respiratory and oxygenation monitoring
- Skin temperature hourly
- Serum sodium concentration
Correct Answer: Continuous respiratory and oxygenation monitoring
Q22. Which statement about naloxone and buprenorphine interaction is true?
- Naloxone reliably and completely reverses buprenorphine due to buprenorphine’s low receptor affinity
- Buprenorphine’s high receptor affinity can limit naloxone’s ability to fully reverse its effects
- Buprenorphine is not an opioid; naloxone has no effect
- Naloxone potentiates buprenorphine’s agonist effects
Correct Answer: Buprenorphine’s high receptor affinity can limit naloxone’s ability to fully reverse its effects
Q23. Which adverse cardiovascular event has been reported after rapid naloxone administration?
- Bradycardia without other signs
- Tachycardia and hypertension
- Prolonged QTc shortening
- Complete heart block as the only effect
Correct Answer: Tachycardia and hypertension
Q24. For safe titration when reversing respiratory depression in opioid-dependent patients, naloxone should be given:
- All at once in a high bolus to avoid withdrawal
- In incremental, titrated doses to restore adequate ventilation without precipitating severe withdrawal
- Only orally over 24 hours
- Combined with large doses of opioid agonists
Correct Answer: In incremental, titrated doses to restore adequate ventilation without precipitating severe withdrawal
Q25. Which laboratory process would B.Pharm students study to understand naloxone stability in solution?
- Polymerase chain reaction (PCR)
- Forced degradation and stability-indicating assay development
- Gram staining
- Therapeutic drug monitoring of lithium
Correct Answer: Forced degradation and stability-indicating assay development
Q26. Which statement about naloxone’s protein binding is correct?
- Naloxone is highly protein bound (>99%) making it long-acting
- Naloxone has low to moderate plasma protein binding, contributing to relatively short duration
- Naloxone does not bind plasma proteins at all
- Protein binding is irrelevant to naloxone pharmaceutics
Correct Answer: Naloxone has low to moderate plasma protein binding, contributing to relatively short duration
Q27. Which storage precaution is appropriate for naloxone injection vials in a pharmacy?
- Store in direct sunlight to keep sterile
- Protect from extremes of temperature and light; follow manufacturer’s label
- Freeze for long-term stability
- Keep diluted in syringes at room temperature for weeks
Correct Answer: Protect from extremes of temperature and light; follow manufacturer’s label
Q28. In formulation design, which excipient would most likely be avoided for an aqueous naloxone solution destined for parenteral use?
- Sterile water for injection or normal saline
- Antioxidants and preservatives acceptable at labeled concentrations
- Non-sterile buffers without validation
- pH-adjusting buffers validated for IV use
Correct Answer: Non-sterile buffers without validation
Q29. Which pharmacological effect is naloxone least likely to reverse?
- Opioid-induced analgesia
- Opioid-induced sedation
- Hypoventilation due to non-opioid CNS depressants
- Opioid-induced miosis
Correct Answer: Hypoventilation due to non-opioid CNS depressants
Q30. A pharmacy student preparing an MCQ on naloxone formulation should note that intranasal bioavailability is generally:
- Equal to 100% of IV bioavailability
- Higher than oral bioavailability but lower than IV bioavailability
- Zero because mucosa cannot absorb naloxone
- Greater than intramuscular bioavailability always
Correct Answer: Higher than oral bioavailability but lower than IV bioavailability
Q31. Which factor influences the need for repeat naloxone dosing after initial reversal?
- Type and half-life of the opioid involved
- Patient hair color
- Time of day only
- Ambient humidity exclusively
Correct Answer: Type and half-life of the opioid involved
Q32. Which statement is true regarding naloxone use by bystanders in the community?
- Naloxone administration by trained laypersons has been shown to reduce opioid overdose mortality
- Naloxone is always harmful if used by non-medical personnel
- Only physicians are allowed to carry naloxone legally in all countries
- Naloxone has no role outside the hospital
Correct Answer: Naloxone administration by trained laypersons has been shown to reduce opioid overdose mortality
Q33. Which monitoring will help detect re-narcotization after naloxone therapy?
- Only blood glucose checks
- Continuous respiratory rate and level of consciousness assessment
- Monitoring hair growth
- Electrocardiograms every minute
Correct Answer: Continuous respiratory rate and level of consciousness assessment
Q34. In industrial pharmacy, which challenge is specific to manufacturing intranasal naloxone spray?
- Ensuring nasal mucosal absorption and appropriate droplet size for deposition
- Preventing oral ingestion after packaging
- Formulating for subdermal implantation
- Creating a taste-masked chewable tablet
Correct Answer: Ensuring nasal mucosal absorption and appropriate droplet size for deposition
Q35. Which clinical scenario suggests naloxone administration is indicated?
- Patient with vomit but normal respiration and responsiveness
- Unresponsive patient with pinpoint pupils and depressed respiratory rate
- Patient with high blood glucose and polyuria
- Patient with allergic rhinitis only
Correct Answer: Unresponsive patient with pinpoint pupils and depressed respiratory rate
Q36. Naloxone’s effect on opioid receptors is best described as:
- Partial agonist activity at mu receptors
- Inverse agonist producing opposite effects to opioids
- Neutral competitive antagonist blocking receptor activation by agonists
- Irreversible covalent receptor modifier
Correct Answer: Neutral competitive antagonist blocking receptor activation by agonists
Q37. Which statement about naloxone metabolism is correct?
- Naloxone is extensively metabolized in the liver to inactive metabolites
- Naloxone is excreted unchanged only in bile
- Naloxone is metabolized to potent opioid agonists
- Naloxone is not subjected to hepatic metabolism
Correct Answer: Naloxone is extensively metabolized in the liver to inactive metabolites
Q38. A pharmacist counseling on naloxone nasal spray should mention which key point?
- Naloxone nasal spray must be swallowed for effect
- Administer into one nostril while patient is supine and watch for response
- Only useful if taken with an opioid analgesic pill
- It is permanent and requires no further medical attention
Correct Answer: Administer into one nostril while patient is supine and watch for response
Q39. Which is a potential serious pulmonary complication reported after naloxone administration?
- Pulmonary edema
- Chronic bronchitis induction
- Permanent bronchiectasis
- Interstitial lung fibrosis after one dose
Correct Answer: Pulmonary edema
Q40. In the context of pharmacovigilance, which adverse reaction following naloxone should be reported?
- Mild, expected improvement in breathing only
- Severe acute withdrawal or unexpected allergic reaction
- Normal pupil dilation consistent with reversal
- Routine bruising at injection site with no other signs
Correct Answer: Severe acute withdrawal or unexpected allergic reaction
Q41. Which property differentiates naloxone from nalmefene?
- Nalmefene is shorter acting than naloxone
- Nalmefene has a longer half-life than naloxone and is used in some settings for longer antagonism
- Both have identical pharmacokinetics and clinical use
- Nalmefene is an opioid agonist, not an antagonist
Correct Answer: Nalmefene has a longer half-life than naloxone and is used in some settings for longer antagonism
Q42. Which quality control test is essential for sterile naloxone injection batches?
- Microbial sterility testing and endotoxin limits
- Taste panel testing
- Color matching to a reference tablet
- Crushing strength for tablets
Correct Answer: Microbial sterility testing and endotoxin limits
Q43. In the setting of mixed opioid and clonidine overdose, naloxone administration will:
- Reverse both clonidine and opioid effects equally
- Reverse opioid effects but not clonidine-induced hypotension and sedation fully
- Worsen clonidine effects immediately
- Convert clonidine into an antagonist
Correct Answer: Reverse opioid effects but not clonidine-induced hypotension and sedation fully
Q44. Which is the most appropriate action if a patient regresses into respiratory depression after initial naloxone reversal?
- Ignore and discharge the patient immediately
- Administer additional naloxone doses and seek definitive care
- Administer oral opioids to counteract withdrawal
- Wait 48 hours before reassessing
Correct Answer: Administer additional naloxone doses and seek definitive care
Q45. Which exam-focused point about naloxone should B.Pharm students remember?
- Naloxone is recommended as a preventative daily medication for chronic pain patients
- Naloxone is the drug of choice for acute opioid overdose reversal and can be given by multiple routes
- Naloxone cures opioid dependence permanently
- Naloxone is primarily used to treat bacterial infections
Correct Answer: Naloxone is the drug of choice for acute opioid overdose reversal and can be given by multiple routes
Q46. Which is a correct statement about naloxone dosing strategy in an emergency to avoid severe withdrawal?
- Give a single large bolus dose to immediately normalize consciousness
- Start with a small titrated dose to restore breathing without full reversal of analgesia
- Administer naloxone only if the patient is alert
- Always co-administer naloxone with flumazenil
Correct Answer: Start with a small titrated dose to restore breathing without full reversal of analgesia
Q47. Which regulatory consideration is relevant when stocking naloxone in a community pharmacy?
- Naloxone is universally banned from community pharmacies
- Many regions permit standing orders or pharmacist protocols to dispense naloxone without individual prescriptions
- Naloxone requires refrigeration in all countries by law
- Naloxone cannot be dispensed to laypersons under any circumstances
Correct Answer: Many regions permit standing orders or pharmacist protocols to dispense naloxone without individual prescriptions
Q48. Which formulation factor is important for intranasal naloxone to maximize absorption?
- Viscosity, droplet size, and pH compatibility with nasal mucosa
- Emulsification for oral swallowing
- Presence of strong systemic preservatives only
- High alcohol content to improve shelf life
Correct Answer: Viscosity, droplet size, and pH compatibility with nasal mucosa
Q49. For teaching pharmacology, which concept does naloxone illustrate well?
- Prodrug activation in the liver
- Competitive receptor antagonism and clinical translation to overdose management
- Enzyme induction leading to faster drug clearance
- Ion channel blockade in cardiac tissue
Correct Answer: Competitive receptor antagonism and clinical translation to overdose management
Q50. Which post‑reversal advice should be given after naloxone use in the field?
- No need for medical evaluation after naloxone if the patient seems better
- Advise immediate medical evaluation because re-narcotization or complications can occur
- Encourage the patient to drive home after recovery
- Advise taking sedatives to prevent withdrawal symptoms
Correct Answer: Advise immediate medical evaluation because re-narcotization or complications can occur
